Vi­a­tris pe­ti­tions FDA over would-be EpiPen com­peti­tor, claim­ing more da­ta nec­es­sary

Vi­a­tris, over the last two years, pulled in more than $750 mil­lion from its EpiPen au­toin­jec­tor, a key emer­gency treat­ment for ana­phy­lax­is. So it should …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.